EG24449A - Purification process - Google Patents

Purification process

Info

Publication number: EG24449A
Authority: EG; Egypt
Prior art keywords: purification process; purification
Prior art date: 2003-03-13

Application number

Other languages

English (en)

Inventor

Ralph Biemans

Carine Goraj

Emmanuel Mertens

Anne Vandercammen

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-13

Filing date

2005-08-22

Publication date

2009-07-13

2003-03-13 Priority claimed from GB0305791A external-priority patent/GB0305791D0/en

2003-03-13 Priority claimed from GB0305792A external-priority patent/GB0305792D0/en

2005-08-22 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2009-07-13 Application granted granted Critical

2009-07-13 Publication of EG24449A publication Critical patent/EG24449A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Pulmonology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Neurology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EGNA2005000491 2003-03-13 2005-08-22 Purification process EG24449A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0305791A GB0305791D0 (en)	2003-03-13	2003-03-13	Detoxification process
GB0305792A GB0305792D0 (en)	2003-03-13	2003-03-13	Purification Process
PCT/EP2004/002641 WO2004081515A2 (en)	2003-03-13	2004-03-11	Purification process for bacterial cytolysin

Publications (1)

Publication Number	Publication Date
EG24449A true EG24449A (en)	2009-07-13

Family

ID=32992596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EGNA2005000491 EG24449A (en)	2003-03-13	2005-08-22	Purification process

Country Status (23)

Country	Link
US (3)	US8084235B2 (is)
EP (1)	EP1601689B1 (is)
JP (2)	JP4597123B2 (is)
KR (1)	KR101052996B1 (is)
CN (1)	CN101818185B (is)
AU (2)	AU2004219910B2 (is)
BR (1)	BRPI0408094A (is)
CA (2)	CA2518669C (is)
CY (1)	CY1107134T1 (is)
DE (1)	DE602004010376T2 (is)
DK (1)	DK1601689T3 (is)
EG (1)	EG24449A (is)
ES (1)	ES2295836T3 (is)
HK (1)	HK1086013A1 (is)
IL (1)	IL210984A0 (is)
IS (1)	IS2587B (is)
MA (1)	MA27666A1 (is)
MX (1)	MXPA05009579A (is)
NO (1)	NO336672B1 (is)
NZ (1)	NZ541969A (is)
PT (1)	PT1601689E (is)
RU (1)	RU2340627C2 (is)
WO (1)	WO2004081515A2 (is)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8084235B2 (en)	2003-03-13	2011-12-27	Glaxosmithkline Biologicals S.A.	Purification process for bacterial cytolysin
GB0421083D0 (en) *	2004-09-22	2004-10-27	Glaxosmithkline Biolog Sa	Purification process
MX2007011709A (es)	2005-03-23	2007-12-11	Oculus Innovative Sciences Inc	Metodo para tratar ulceras de la piel utilizando solucion de agua con potencial oxido reductor.
MX2007016237A (es)	2005-06-27	2008-03-07	Glaxosmithkline Biolog Sa	Composicion inmunogenica.
TW201350129A (zh)	2005-12-22	2013-12-16	Glaxosmithkline Biolog Sa	包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
US20070196434A1 (en)	2006-01-20	2007-08-23	Oculus Innovative Sciences, Inc.	Methods of preventing or treating sinusitis with oxidative reductive potential water solution
MX2009002560A (es)	2006-09-07	2009-03-20	Glaxosmithkline Biolog Sa	Vacuna.
CN101855238B (zh) *	2007-04-16	2014-09-17	米纳瓦克斯有限责任公司	融合蛋白疫苗
AU2008248640A1 (en)	2007-05-02	2008-11-13	Glaxosmithkline Biologicals S.A.	Vaccine
BRPI0813307C1 (pt)	2007-06-26	2021-05-25	Glaxosmithkline Biologicals Sa	composição imunogênica, vacina, e, processo para fabricar a vacina
WO2009127676A1 (en)	2008-04-16	2009-10-22	Glaxosmithkline Biologicals S.A.	Vaccine
EP2328613A1 (en) *	2008-08-28	2011-06-08	GlaxoSmithKline Biologicals S.A.	Vaccine
WO2010125480A1 (en)	2009-04-30	2010-11-04	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
WO2010132833A1 (en)	2009-05-14	2010-11-18	The Regents Of The University Of Michigan	Streptococcus vaccine compositions and methods of using the same
BRPI1011886B1 (pt)	2009-06-15	2022-05-03	Invekra, S.A.P.I De C.V	Solução antimicrobiana de baixo ph
NZ599059A (en)	2009-09-03	2014-05-30	Pfizer Vaccines Llc	Pcsk9 vaccine
AU2010310919B2 (en)	2009-10-30	2015-05-07	Glaxosmithkline Biologicals S.A.	Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2680883B1 (en)	2011-03-02	2018-09-05	Pfizer Inc	Pcsk9 vaccine
CN103619871B (zh) *	2011-04-22	2016-12-14	惠氏有限责任公司	涉及突变体难辨梭菌毒素的组合物及其方法
EA201391456A1 (ru)	2011-05-17	2014-05-30	Глаксосмитклайн Байолоджикалс С.А.	ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
WO2014045621A1 (ja) *	2012-09-19	2014-03-27	国立大学法人大阪大学	肺炎球菌表面タンパク質ａを含む肺炎球菌ワクチン
EP2927312B1 (en) *	2012-11-30	2022-10-19	Bioneer Corporation	Apparatus for automatically preparing cell-free proteins and method for preparing proteins using the same
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
SI3096783T1 (sl)	2014-01-21	2021-09-30	Pfizer Inc.	Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
PT3583947T (pt)	2014-01-21	2023-12-14	Pfizer	Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
CN114887048A (zh)	2014-01-21	2022-08-12	辉瑞公司	包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2930318T3 (es)	2014-02-14	2022-12-09	Pfizer	Conjugados glucoproteicos inmunogénicos
AU2016207820B2 (en)	2015-01-15	2020-12-17	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
US9218427B1 (en) *	2015-01-21	2015-12-22	Maana, Inc.	Dynamic semantic models having multiple indices
WO2016168815A1 (en) *	2015-04-16	2016-10-20	Iventprise LLC	Bordetella pertussis immunogenic vaccine compositions
MY192183A (en)	2015-07-21	2022-08-05	Pfizer	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Vaccine
EP3377098A1 (en)	2015-11-20	2018-09-26	Pfizer Inc	Immunogenic compositions for use in pneumococcal vaccines
GB201603029D0 (en) *	2016-02-22	2016-04-06	Glaxosmithkline Biolog Sa	Vaccine
IL264552B2 (en)	2016-08-05	2023-04-01	Sanofi Pasteur Inc	A multivalent pneumococcal protein-polysaccharide conjugate preparation
TWI770044B (zh)	2016-08-05	2022-07-11	南韓商Ｓｋ生物科技股份有限公司	多價肺炎球菌多醣-蛋白質共軛物組成物(一)
US20190360013A1 (en) *	2016-12-02	2019-11-28	President And Fellows Of Harvard College	Processive Template Independent DNA Polymerase Variants
CN118662649A (zh)	2016-12-30	2024-09-20	Vaxcyte公司	具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en)	2016-12-30	2024-04-09	Vaxcyte, Inc.	Conjugated vaccine carrier proteins
CA3050622A1 (en)	2017-01-20	2018-07-26	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
CN110225757A (zh)	2017-01-31	2019-09-10	默沙东公司	由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
JP7132954B2 (ja)	2017-06-10	2022-09-07	インベントプライズリミテッドライアビリティカンパニー	改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
US10729763B2 (en)	2017-06-10	2020-08-04	Inventprise, Llc	Mixtures of polysaccharide-protein pegylated compounds
MX2020002555A (es)	2017-09-07	2020-09-25	Merck Sharp & Dohme	Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
BR122021023687A8 (pt)	2017-12-06	2023-02-07	Merck Sharp & Dohme	Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
JP7288451B2 (ja)	2018-02-05	2023-06-07	サノフィパスツールインコーポレイティッド	多価肺炎球菌多糖体－タンパク質複合体組成物
MX2020008198A (es)	2018-02-05	2020-09-22	Sanofi Pasteur Inc	Composicion del conjugado proteina-polisacarido multivalente neumococica.
AU2019256218A1 (en)	2018-04-18	2020-12-03	Sk Bioscience Co., Ltd.	Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
EP3894431A2 (en)	2018-12-12	2021-10-20	GlaxoSmithKline Biologicals SA	Modified carrier proteins for o-linked glycosylation
EP3893926A1 (en)	2018-12-12	2021-10-20	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
TWI788610B (zh)	2018-12-19	2023-01-01	美商默沙東有限責任公司	包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
JP7239509B6 (ja)	2019-02-22	2023-03-28	ファイザー・インク	細菌多糖類を精製するための方法
CA3136278A1 (en)	2019-04-10	2020-10-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2021021729A1 (en)	2019-07-31	2021-02-04	Sanofi Pasteur Inc.	Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
AU2020375214B2 (en)	2019-11-01	2024-02-08	Pfizer Inc.	Escherichia coli compositions and methods thereof
JP2021132644A (ja)	2020-02-21	2021-09-13	ファイザー・インク	糖の精製
KR20220143910A (ko)	2020-02-23	2022-10-25	화이자 인코포레이티드	에스케리키아 콜라이 조성물 및 그의 방법
CA3191005A1 (en)	2020-08-10	2022-02-17	Inventprise, Inc.	Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US20230383324A1 (en)	2020-10-22	2023-11-30	Pfizer Inc.	Methods for purifying bacterial polysaccharides
IL302362A (en)	2020-10-27	2023-06-01	Pfizer	Escherichia coli compositions and methods thereof
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
IL302413A (en)	2020-11-04	2023-06-01	Pfizer	Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en)	2020-12-23	2022-06-30	Pfizer Inc.	E. coli fimh mutants and uses thereof
TW202245835A (zh)	2021-02-04	2022-12-01	美商默沙東有限責任公司	用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024517780A (ja)	2021-05-03	2024-04-23	ファイザー・インク	細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en)	2021-05-03	2022-11-10	Pfizer Inc.	Vaccination against pneumoccocal and covid-19 infections
TWI857300B (zh)	2021-05-28	2024-10-01	美商輝瑞大藥廠	包含結合之莢膜醣抗原的免疫原組合物及其用途
JP2024521847A (ja)	2021-05-28	2024-06-04	ファイザー・インク	コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
AU2023207315A1 (en)	2022-01-13	2024-06-27	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
KR20250008122A (ko)	2022-05-11	2025-01-14	화이자 인코포레이티드	보존제를 갖는 백신 제형의 제조 방법
WO2024084397A1 (en)	2022-10-19	2024-04-25	Pfizer Inc.	Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en)	2022-11-22	2024-05-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en)	2022-12-01	2024-06-06	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en)	2023-03-30	2024-10-03	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024238731A1 (en)	2023-05-18	2024-11-21	Merck Sharp & Dohme Llc	Compounds and adjuvant formulations useful in pneumococcal vaccines
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8807860D0 (en) *	1988-04-05	1988-05-05	Connaught Lab	Pertussis vaccine
HUT58804A (en) *	1988-12-16	1992-03-30	James Cleland Paton	Process for producing pneumolysine mutants and pneumococcus vaccines
DE4133707A1 (de) *	1991-10-11	1993-04-15	Behringwerke Ag	Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
GB9216351D0 (en) *	1992-07-31	1992-09-16	Wellcome Found	Vaccine production
US5565204A (en) *	1994-08-24	1996-10-15	American Cyanamid Company	Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
ATE355363T1 (de)	1995-01-27	2006-03-15	Genencor Int	Verfahren zur extraktion von enzymen unter verwendung von tensiden
US5877298A (en) *	1995-05-04	1999-03-02	Connaught Lab	Acellular pertussis vaccines and methods of preparing thereof
US5667786A (en) *	1995-06-07	1997-09-16	Novavax, Inc.	Method for treating tumors with a toxin
HUP0002475A3 (en) *	1997-07-21	2002-01-28	Baxter Healthcare S A Wallisel	Modified immunogenic pneumolysin compositions as vaccines
HU229968B1 (hu) *	1999-03-19	2015-03-30	Smithkline Beecham Biologicals S.A	Sztreptokokkusz oltóanyag
JP4132694B2 (ja) *	2000-03-10	2008-08-13	独立行政法人科学技術振興機構	受容体認識部位が保存された生理活性物質の誘導体及びその使用方法
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
US8084235B2 (en)	2003-03-13	2011-12-27	Glaxosmithkline Biologicals S.A.	Purification process for bacterial cytolysin
GB0421083D0 (en)	2004-09-22	2004-10-27	Glaxosmithkline Biolog Sa	Purification process

2004
- 2004-03-11 US US10/549,064 patent/US8084235B2/en not_active Expired - Fee Related
- 2004-03-11 AU AU2004219910A patent/AU2004219910B2/en not_active Ceased
- 2004-03-11 EP EP04719447A patent/EP1601689B1/en not_active Expired - Lifetime
- 2004-03-11 NZ NZ541969A patent/NZ541969A/en not_active IP Right Cessation
- 2004-03-11 CA CA2518669A patent/CA2518669C/en not_active Expired - Fee Related
- 2004-03-11 DE DE602004010376T patent/DE602004010376T2/de not_active Expired - Lifetime
- 2004-03-11 DK DK04719447T patent/DK1601689T3/da active
- 2004-03-11 WO PCT/EP2004/002641 patent/WO2004081515A2/en active Application Filing
- 2004-03-11 MX MXPA05009579A patent/MXPA05009579A/es active IP Right Grant
- 2004-03-11 CA CA2812817A patent/CA2812817C/en not_active Expired - Fee Related
- 2004-03-11 KR KR1020057017163A patent/KR101052996B1/ko not_active IP Right Cessation
- 2004-03-11 CN CN201010157455.6A patent/CN101818185B/zh not_active Expired - Fee Related
- 2004-03-11 JP JP2006504684A patent/JP4597123B2/ja not_active Expired - Fee Related
- 2004-03-11 RU RU2005125832/13A patent/RU2340627C2/ru not_active IP Right Cessation
- 2004-03-11 BR BRPI0408094-7A patent/BRPI0408094A/pt not_active Application Discontinuation
- 2004-03-11 ES ES04719447T patent/ES2295836T3/es not_active Expired - Lifetime
- 2004-03-11 PT PT04719447T patent/PT1601689E/pt unknown
2005
- 2005-08-18 IS IS7993A patent/IS2587B/is unknown
- 2005-08-22 EG EGNA2005000491 patent/EG24449A/xx active
- 2005-09-06 NO NO20054134A patent/NO336672B1/no not_active IP Right Cessation
- 2005-09-09 MA MA28487A patent/MA27666A1/fr unknown
2006
- 2006-05-24 HK HK06105983.2A patent/HK1086013A1/xx not_active IP Right Cessation
2008
- 2008-01-10 CY CY20081100036T patent/CY1107134T1/el unknown
2010
- 2010-08-10 AU AU2010212257A patent/AU2010212257B2/en not_active Ceased
- 2010-08-11 JP JP2010180165A patent/JP5683866B2/ja not_active Expired - Fee Related
2011
- 2011-02-01 IL IL210984A patent/IL210984A0/en unknown
- 2011-08-31 US US13/222,066 patent/US8309327B2/en not_active Expired - Fee Related
2012
- 2012-09-27 US US13/628,632 patent/US8815254B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MA27666A1 (fr)	2005-12-01
US8084235B2 (en)	2011-12-27
CA2812817A1 (en)	2004-09-23
EP1601689A2 (en)	2005-12-07
IL210984A0 (en)	2011-04-28
DK1601689T3 (da)	2008-03-25
US20140010843A1 (en)	2014-01-09
WO2004081515A3 (en)	2004-11-11
ES2295836T3 (es)	2008-04-16
US8815254B2 (en)	2014-08-26
US20070026010A1 (en)	2007-02-01
EP1601689B1 (en)	2007-11-28
KR101052996B1 (ko)	2011-07-29
IS7993A (is)	2005-08-18
AU2004219910A1 (en)	2004-09-23
US8309327B2 (en)	2012-11-13
CN101818185B (zh)	2016-05-25
AU2004219910B2 (en)	2010-06-17
AU2010212257B2 (en)	2012-08-30
CY1107134T1 (el)	2012-10-24
HK1086013A1 (en)	2006-09-08
JP2006520205A (ja)	2006-09-07
NO20054134D0 (no)	2005-09-06
PT1601689E (pt)	2008-01-04
JP4597123B2 (ja)	2010-12-15
US20110311577A1 (en)	2011-12-22
BRPI0408094A (pt)	2006-02-14
JP2010259448A (ja)	2010-11-18
DE602004010376D1 (de)	2008-01-10
CA2812817C (en)	2016-12-20
JP5683866B2 (ja)	2015-03-11
CN101818185A (zh)	2010-09-01
RU2340627C2 (ru)	2008-12-10
DE602004010376T2 (de)	2008-10-23
AU2010212257A1 (en)	2010-09-02
NO336672B1 (no)	2015-10-19
CA2518669A1 (en)	2004-09-23
RU2005125832A (ru)	2006-04-27
KR20050111357A (ko)	2005-11-24
CA2518669C (en)	2014-07-29
WO2004081515A2 (en)	2004-09-23
IS2587B (is)	2010-02-15
MXPA05009579A (es)	2005-11-17
NO20054134L (no)	2005-10-04
NZ541969A (en)	2008-01-31

Publication	Publication Date	Title
EG24449A (en)	2009-07-13	Purification process
GB0306432D0 (en)	2003-04-23	Process
GB0313661D0 (en)	2003-07-16	Process
GB0316756D0 (en)	2003-08-20	Process
GB0303659D0 (en)	2003-03-19	Process
EP1612274A4 (en)	2011-05-11	PROCESS FOR PURIFYING DIFRUCTOSE-DIANHYDRIDE III
GB0209222D0 (en)	2002-06-05	Purification process
GB0314739D0 (en)	2003-07-30	Electrodeionisation process
GB0313110D0 (en)	2003-07-09	Process
GB0311725D0 (en)	2003-06-25	Process
GB0307259D0 (en)	2003-05-07	Process
TWI350829B (en)	2011-10-21	Purification process
GB0312451D0 (en)	2003-07-09	Process
GB0308672D0 (en)	2003-05-21	Process
GB0313031D0 (en)	2003-07-09	Process
GB0327179D0 (en)	2003-12-24	Purification method
GB0316872D0 (en)	2003-08-20	Process
GB0300733D0 (en)	2003-02-12	Process
GB0314380D0 (en)	2003-07-23	Purification process
GB0305792D0 (en)	2003-04-16	Purification Process
GB0314960D0 (en)	2003-07-30	Process
GB0209223D0 (en)	2002-06-05	Purification process
GB0216451D0 (en)	2002-08-21	Purification process
GB0222219D0 (en)	2002-10-30	Purification process
GB0317218D0 (en)	2003-08-27	Purification means